sutrovax.comHealthcareFounded: 2013Funding to Date: $173.25MM
Developer of conjugate and novel complex antigen-based vaccines intended to prevent serious infectious diseases. The company's cell-free protein synthesis platform permits site-specific conjugation, enabling the creation of conjugate vaccines with the potential to deliver heightened immunity and broader protection.